ETFs & MarketsPremiumTruist Price Target Hike on Eli Lilly Signals ETF Rebalancing Pressure
Truist has upwardly adjusted its price target for Eli Lilly, citing sustained strength in its incretin-based therapeutic portfolio. This analyst move highlights the growing concentration of weight-loss drug leaders within major healthcare indices.
Published 2 hours ago
Read more →